Payment overview · 2025
General Payments
$554.69
7 reported records · 5 companies
Healthcare provider profile · identity verified
Niranjana Parikh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1134282924
Verified facts
What the public records show
CMS Open Payments records show Niranjana Parikh, MD received $554.69 in general payments during 2025 across 7 reported records.
Abbott Laboratories accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $232.67 | 42.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.18 | 26.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $128.69 | 23.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.39 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.76 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $554.69 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $232.67 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $149.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $128.69 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
196 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 439 | 160 |
| Metformin Hcl | Metformin Hcl | 289 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 94 |
| Farxiga | Dapagliflozin Propanediol | 196 | 47 |
| Jardiance | Empagliflozin | 164 | 38 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 161 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 130 | 37 |
| Losartan Potassium | Losartan Potassium | 124 | 44 |
| Omeprazole | Omeprazole | 124 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 48 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 104 | 25 |
| Valsartan | Valsartan | 100 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 24 |
| Januvia | Sitagliptin Phosphate | 89 | 23 |
| Simvastatin | Simvastatin | 87 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 63 | 21 |
| Carvedilol | Carvedilol | 62 | 20 |
| Allopurinol | Allopurinol | 58 | 22 |
| Azithromycin | Azithromycin | 58 | 53 |
| Trulicity | Dulaglutide | 56 | 11 |
| Linzess | Linaclotide | 54 | 13 |
| Fenofibrate | Fenofibrate | 52 | 16 |
| Gabapentin | Gabapentin | 50 | 26 |
| Glimepiride | Glimepiride | 49 | 15 |
| Lisinopril | Lisinopril | 49 | 19 |
| Famotidine | Famotidine | 48 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 44 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Meloxicam | Meloxicam | 42 | 21 |
| Alendronate Sodium | Alendronate Sodium | 41 | 17 |
| Donepezil Hcl | Donepezil Hcl | 41 | 16 |
| Glipizide Er | Glipizide | 41 | 12 |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 19 |
| Ozempic | Semaglutide | 34 | 12 |
| Furosemide | Furosemide | 32 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 11 |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | 15 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 15 |
| Atenolol | Atenolol | 24 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 24 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | 14 |
| Eliquis | Apixaban | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 15 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 20 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | 13 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $554.69 · 7 records | Abbott Laboratories | BREZTRI, FREESTYLE LIBRE 3, Korlym, OTEZLA, REPATHA, VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error